A. Didier

发表

Cyclosporins: structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor.

R. Traber, F. Loor, F. Tiberghien, 2002, Journal of medicinal chemistry.

Decreased biotolerability for ivermectin and cyclosporin a in mice exposed to potent P‐glycoprotein inhibitors

F. Loor, A. Didier, 1995, International journal of cancer.

The abamectin derivative ivermectin is a potent P‐glycoprotein inhibitor

F. Loor, A. Didier, Francis Loor, 1996, Anti-cancer drugs.

Number and Replating Capacity of Endothelial Colony‐Forming Cells are Telomere Length Dependent: Implication for Human Atherogenesis

A. Aviv, S. Visvikis-Siest, Tsung-Po Lai, 2021, Journal of the American Heart Association.

Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter.

T. Kurome, F. Loor, F. Tiberghien, 2000, Journal of medicinal chemistry.

Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice.

S. Froidevaux, A. Pourtier-Manzanedo, F. Loor, 1995, Toxicology.

Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.

R. Traber, F. Loor, F. Tiberghien, 2002, Journal of medicinal chemistry.

Expression of P-glycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin A-responding mouse spleen cells by P-glycoprotein blockers.

A. Pourtier-Manzanedo, F. Loor, A. Didier, 1992, Oncology research.

The MultiScreen filtration system to measure chemoattractant-induced release of leukocyte granule enzymes by differentiated HL-60 cells or normal human monocytes.

A. Bohbot, F. Loor, F. Tiberghien, 1999, Journal of immunological methods.

SDZ PSC 833 and SDZ 280–446 are the most active of various resistance‐modifying agents in restoring rhodamine‐123 retention within multidrug resistant P388 cells

C. Muller, A. Pourtier-Manzanedo, F. Loor, 1992, Anti-cancer drugs.